Intel Corp vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Intel Corp trades at $108.55 (market cap $566.04B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.22 (market cap $2.27B). The key difference: Intel Corp is far larger — about 249.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Intel Corp pays a 2.24% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| INTC | SLS | |
|---|---|---|
Market Cap | $566.04B | $2.27B |
Volume | 118,475,837 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $140.94 | $15.46 |
52-Week Low | $33.62 | $1.39 |
Typical Hold Time | 116 Days | — |
Enterprise Value | $586.85B | $2.14B |
Dividend Yield | 2.24% | — |
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $113.12, up 0.55% today, with a bullish technical signal and recent earnings beats. The stock has surged over 220% in 2026, driven by AI momentum and foundry growth, though fundamentals show negative net income margins and elevated valuations. Cash flow improved in 2025, but revenue remains below 2022 peaks amid intense competition.
Outlook hinges on foundry turnaround execution; upside exists if Intel captures external customers for advanced nodes, but high debt and margin pressures pose risks. Analyst consensus is cautious with a $111.72 target, slightly below current price, reflecting skepticism on sustainability despite recent gains.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →